OTHER
No treatment given
Participants will not get any medicine during this study.
Status
Completed
Phase
Phase 1
Enrollment
164
Locations
1
Results
Not posted
Publications
0
Study summary
Part A: The study will look at participants appetite and energy intake and also look at the mechanisms of brain associated with appetite and food intake. Participants will not get any medicine and will be in a group that will be compared to another group receiving a weight-loss medicine. The study will last for about 6 months. Part B: The study will look at how CagriSema works on participants appetite and energy intake and will be compared with a ''dummy'' medicine. The study will also look at how participants brain works when participants take the medicine. Participants will either get CagriSema or ''dummy'' medicine.
Interventions
OTHER
Participants will not get any medicine during this study.
DRUG
Participants will receive subcutaneous (s.c.) injections of Cagrilintide and Semaglutide.
DRUG
Participants will receive subcutaneous (s.c.) injections of placebo matched to Cagrilintide and Semaglutide.
Timeline
First posted
Feb 20, 2024
Study start
Feb 15, 2024
Primary completion
Apr 7, 2025
Study completion
Dec 8, 2025
Results posted
Not reported
Registry updated
Jan 8, 2026
Outcomes
Change in mean postprandial appetite score based on visual analogue scale (VAS)
Time frame · Baseline to week 24
Measured in millimeter. VAS appetite questions record the participants' sensations within Hunger, Satiety, Fullness and Prospective food consumption by the participants on a paper printed scale line from 0 to 100 mm. The appetite score will be calculated as \[hunger + (100 - satiety) + (100 - fullness) + prospective food consumption\]/4. Scores of 0 mm are worst and scores of 100 mm are best.
Change in mean postprandial VAS ratings of: hunger, fullness, satiety and prospective food consumption
Time frame · Baseline to week 24
Measured in millimeter
Change in average DAILY EATS questionnaire scores over one week for: average hunger, worst hunger, appetite, cravings, satiety and eating drivers index composite score
Time frame · Baseline pre-treatment ((Day 4 - Day 10) to treatment (Day 156 - Day 162))
Measured in score points. The DAILY EATS is a 5-item, self-reported measure assessing key eating-related factors (Worst and Average Hunger, Appetite, Cravings, and Satiety). Additionally, an eating drivers index (EDI), comprising the related items Worst Hunger, Appetite, and Cravings can be calculated using this questionnaire. An 11-point numerical rating scale (0-10) is used for each item, with a higher value indicating more hunger, bigger appetite, stronger cravings, or greater satiety.
Change in control of eating questionnaire (COEQ), 4 domains: craving control score, positive mood score, craving for sweets score and craving for savoury food score
Time frame · Baseline to week 24
Measured in score points. The COEQ is a self-reported measure assessing various aspects of eating behaviour and related psychological factors. The COEQ has 19 different questions designed to assess the intensity and type of food cravings, as well as subjective sensations of appetite and mood. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control (0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); Higher score represents a greater level of Craving Control.
Change in power of food questionnaire for: food available score, food present score, food tasted score and composite score
Time frame · Baseline to week 24
Measured in score points. The power of food questionnaire measures three factors that correspond to different levels of food proximity and reflect responsiveness to food-abundant environments: food available (food that is available, but not physically present), food present (food that is present, but not tasted), and food tasted (food that is tasted, but not consumed). Moreover, an aggregate score is calculated as the mean of the three subdomains. The questionnaire consists of 15 questions, and the participants will be asked to rate their agreement or disagreement with each statement on a 5-point scale (ranging from "strongly disagree" to "strongly agree").
Change in blood oxygen level dependant (BOLD) response to food cues in the brain reward areas
Time frame · Baseline to week 24
Measured in percentage
Relative change in total energy intake during ad libitum lunch, evening meal and snackbox
Time frame · Baseline to week 24
Measured in percentage
Change in percent energy intake of high fat, sweet food in total ad libitum energy intake in the evening snack box
Time frame · Baseline to week 24
Measured in percentage point
Change in total energy intake during ad libitum lunch, evening meal and snackbox
Time frame · Baseline to week 24
Measured in kilojoules
Change in total amount of food consumed during ad libitum lunch, evening meal and snackbox
Time frame · Baseline to week 24
Measured in grams
Change in body weight
Time frame · Baseline to week 24
Measured in percentage
Eligibility
Inclusion Criteria: * Male or female * Aged 18-65 years (both inclusive) at the time of signing informed consent * Right-handed as evaluated by the Edinburgh Handedness Inventory * Body weight less than or equal to 180 kilogram at screening For Part A: * A score of 7 or less on the 16-item Disinhibition subscale of the Three Factor Eating Questionnaire * Body mass index between 18.5 and 24.9 kilogram per meter square (both inclusive) at screening For Part B: * A score of 8 or more on the 16-item Disinhibition subscale of the Three Factor Eating Questionnaire * Body mass index equal to or above 27.0 kilogram per meter square. Overweight should be due to excess adipose tissue, as judged by the investigator Exclusion Criteria: * Contraindication for magnetic resonance scanning For Part B: * Glycated haemoglobin greater than or equal to 6.5 % (48 millimoles per mole) at screening * History of type 1 or type 2 diabetes mellitus
Study locations
Germany. Showing up to 24 locations stored in the fast local snapshot.
Charité - Campus Charité Mitte - Charité Research Organisation GmbH
Berlin, Germany
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Novo Nordisk · Obesity · Type 2 Diabetes
Phase 3
Recruiting
2,500
2026-07
Novo Nordisk · Obesity
Phase 3
Active, not recruiting
609
2026-07
Novo Nordisk · Obesity
Phase 3
Active, not recruiting
3,400
2026-07
Novo Nordisk · Cardiovascular Disease
Phase 3
Active, not recruiting
7,101
2026-07
Novo Nordisk · Diabetes Mellitus, Type 2
Phase 3
Completed
1,023
2026-07
Novo Nordisk · Overweight · Obesity
Phase 3
Recruiting
460
2026-07
Novo Nordisk · Diabetes Mellitus, Type 2
Phase 2
Withdrawn
0
2026-07
Novo Nordisk · Overweight · Obesity
Phase 3
Withdrawn
0
2026-07
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.